Increase lipid tear thickness after botulinum neurotoxin A injection in patients with blepharospasm and hemifacial spasm

被引:14
|
作者
Ho, Ren-Wen [1 ,2 ,3 ]
Fang, Po-Chiung [1 ,2 ]
Chao, Tsai-Ling [2 ,4 ]
Chien, Chun-Chih [2 ,4 ]
Kuo, Ming-Tse [1 ,2 ]
机构
[1] Kaohsiung Chang Gung Mem Hosp, Dept Ophthalmol, Kaohsiung, Taiwan
[2] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan
[3] Kaohsiung Med Univ, Grad Inst Clin Med, Coll Med, Kaohsiung, Taiwan
[4] Kaohsiung Chang Gung Mem Hosp, Dept Lab Med, Kaohsiung, Taiwan
来源
SCIENTIFIC REPORTS | 2018年 / 8卷
关键词
TOXIN TYPE-A; BENIGN ESSENTIAL BLEPHAROSPASM; LONG-TERM EFFICACY; SAFETY; MUSCLE;
D O I
10.1038/s41598-018-26750-5
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The aim of this study was to investigate changes in the tear film lipid layer thickness (LLT) and aqueous tear production after botulinum neurotoxin A (BoNT) injection in patients with benign essential blepharospasm (BEB) and hemifacial spasm (HFS). Eleven and six patients with BEB and HFS, respectively, who received BoNT injection were consecutively enrolled in this prospective study. The blepharospasm disability index (BSDI), blink pattern, dry eye symptoms, Schirmer test 1 findings, LLT, eyelid performance, and corneal integrity were evaluated before and after treatment. Both BEB and HSF patients experienced remarkable relief from spasms and ocular discomfort after BoNT injection. LLT, the partial blink rate, the snap-back time, the lid distraction distance, and lateral canthal laxity were significantly increased at 1 month after treatment. There were no significant changes in Schirmer test 1 findings and meibomian gland dropout. Our findings suggest that LLT, a decisive factor for tear film stability, significantly increases at 1 month after BoNT injection for BEB and HFS. A decrease in BSDI and an increase in the snap-back time may contribute to the increase in LLT; this mechanism is probably responsible for the relief from dryness after BoNT injection in patients with facial movement disorders.
引用
收藏
页数:9
相关论文
共 39 条
  • [1] Frequency of Hemorrhagic Side Effects of Botulinum Neurotoxin Treatment in Patients with Blepharospasm and Hemifacial Spasm on Antithrombotic Medication
    Wenninger, Fiona Carolin
    Wabbels, Bettina
    TOXINS, 2022, 14 (11)
  • [2] An objective tool to measure the effect of botulinum toxin in blepharospasm and hemifacial spasm
    Osaki, M. H.
    Osaki, T. H.
    Garcia, D. M.
    Osaki, T.
    Gameiro, G.
    Belfort, R., Jr.
    Cruz, A. A. V.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 (08) : 1487 - 1492
  • [3] A Review of Tolerance and Safety Profiles of Long-Term Botulinum Neurotoxin Type A in Asian Patients with Hemifacial Spasm and Benign Essential Blepharospasm
    Lai, Kenneth K. A. Hei
    Tsang, Alan
    Kuk, Andrew K. T.
    Ko, Callie K. L.
    Chan, Edwin
    Ko, Simon T. C.
    NEURO-OPHTHALMOLOGY, 2021, 45 (05) : 293 - 300
  • [4] Botulinum Toxin Treatment of Blepharospasm, Orofacial/Oromandibular Dystonia, and Hemifacial Spasm
    Karp, Barbara Illowsky
    Alter, Katharine
    SEMINARS IN NEUROLOGY, 2016, 36 (01) : 84 - 91
  • [5] Effect of previous botulinum neurotoxin treatment on microvascular decompression for hemifacial spasm
    Wang, Xuhui
    Thirumala, Parthasarathy D.
    Shah, Aalap
    Gardner, Paul
    Habeych, Miguel
    Crammond, Donald J.
    Balzer, Jeffrey
    Horowitz, Michael
    NEUROSURGICAL FOCUS, 2013, 34 (03)
  • [6] 12-year effectiveness and safety of botulinum toxin type A for the treatment of blepharospasm and hemifacial spasm
    Colorado-Ochoa, Hector J.
    Tenorio-Gonzalez, Victoria G.
    REVISTA MEXICANA DE NEUROCIENCIA, 2024, 25 (04): : 109 - 114
  • [7] Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm
    Cannon, Paul S.
    MacKenzie, Kenneth R.
    Cook, Anne E.
    Leatherbarrow, Brian
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2010, 38 (07) : 688 - 691
  • [8] Botulinum toxin for blepharospasm and hemifacial spasm: stability of duration of effect and dosage over time
    Drummond, GT
    Hinz, BJ
    CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2001, 36 (07): : 398 - 403
  • [9] Clinical and psychological factors influencing botulinum toxin efficacy in the treatment of hemifacial spasm and blepharospasm
    Burbaud, P
    Arnaud, A
    Burbaud, A
    Lagueny, A
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 1995, 18 (12): : 751 - 757
  • [10] Patient Characteristics and Real-World Use of Botulinum Toxins for the Treatment of Cervical Dystonia, Blepharospasm, and Hemifacial Spasm
    Hast, Michael A.
    Kong, Amanda M.
    Desai, Shaina
    Back, Soo
    Syed, Sahar
    Holmes, Jordan
    TOXINS, 2024, 16 (08)